IGMS - IGM Biosciences Announces Retirement of Chairman Michael Loberg Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson Ph.D. to Board of Directors | Benzinga
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chairman, effective October 3, 2023. Dr. Loberg has served as a member of the IGM Biosciences Board of Directors since 2015 and as Chairman of the Board since 2018.
IGM Biosciences is also pleased to announce the appointment of Elizabeth H.Z. Thompson, Ph.D. to its Board of Directors. Dr. Thompson is an accomplished drug development professional who has been involved in the development of important marketed medicines, most recently as the Executive Vice President of Research and Development at Horizon Therapeutics.
"Dr. Loberg has played a pivotal role in the development of IGM Biosciences over the last eight years," said Fred Schwarzer, Chief Executive Officer of IGM Biosciences. "As a member and Chairman of our Board of Directors, he has provided vital strategic advice and guidance through the creation, research and initial clinical development of our IgM based antibody platform and through multiple private and public equity financings, including our initial public offering, as well as our ...